No Data
No Data
Xuantai Medicine (688247.SH): Has not developed class 1 new drugs, currently providing preparation CRO/CMO services to domestic and foreign new drug companies and research institutions.
On July 19th, Gelunhui reported that an investor asked Xuantai Pharmaceutical (688247.SH) on the investor interactive platform whether the company is also developing innovative drugs. The company replied that it has not developed Category 1 new drugs. Currently, the company provides formulation CRO/CMO services to domestic and foreign new drug companies and research institutions. Previously, Xuantai Pharmaceuticals was awarded the "Top Ten Drug Innovation Service Institutions of the Year" at the fourth Securities Times Drug Innovation and Public Welfare Awards for its outstanding performance in many areas.
Xuantai Medicine (688247.SH): does not involve synthetic biology related business.
Xuantai Pharmaceuticals (688247.SH) stated on the interactive platform on July 19th that the company does not involve synthetic biology related business.
Xuantai Pharmaceuticals (688247.SH): The company did not implement share repurchase in June.
On June 2024, Xuantai Pharmaceuticals (688247.SH) announced that the company did not implement share repurchases. As of June 30, 2024, the company had cumulatively repurchased 4,186,109 shares through the Shanghai Stock Exchange trading system in a centralized competitive bidding transaction, accounting for 0.92% of the company's total share capital of 453,340,000 shares. The highest purchase price was 8.98 yuan/share, the lowest purchase price was 8.00 yuan/share, and the total amount paid was 35,005,569.17 yuan (excluding stamp duty, transaction commission, and other transaction costs).
Sinotherapeutics Secures Regulatory Nod for Two Drugs
Sinotherapeutics, (SHA:688247) through its subsidiary, Jiangsu Xuantai Pharmaceutical, received approval from China's National Medical Products Administration for two drugs, according to a Wednesday f
Xuantai Pharma (688247.SH): The products Olaparib tablets and Ixempra tablets have obtained pharmaceutical registration certificates.
On June 25th, Gelunhui announced that Xuantai Pharmaceuticals (688247.SH) and its wholly-owned subsidiary Jiangsu Xuantai Pharmaceutical Co., Ltd. received official approval from the National Medical Products Administration for their OlaParib tablets and Exemestane tablets respectively. OlaParib tablets are indicated for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The indications for Exemestane tablets are as follows: adjuvant therapy for early invasive breast cancer in postmenopausal women with estrogen receptor-positive tumors who have been treated with tamoxifen for 2-3 years, until a total of 5 years of adjuvant endocrine therapy is completed.
Xuan Tai Medicine (688247.SH) annual equity distribution for 2023: 0.41 yuan per 10 shares. Registration of shareholdings will take place on June 27th.
Zhitong Finance APP reported that Xuantai Medicine (688247.SH) released its 2023 annual equity distribution implementation announcement, based on the total share capital registered on the day of implementing the equity distribution registration, subtracting the share balance of the company's repurchase dedicated securities account, all shareholders will receive a cash dividend of 0.41 yuan (tax included) for every 10 shares. The share registration date is 2024/6/27, and the ex-right (ex-dividend) date is 2024/6/28.
No Data